UniProt O43353
Receptor-interacting serine/threonine-protein kinase 2 (O43353)
Receptor-interacting serine/threonine-protein kinase 2 (UniProt O43353), EC 2.7.10.2, 2.7.11.1: 56 experimental structures on GenesisL1, 24 ligands bound, 154 pockets. Binding sites, pockets, druggability and 3D structures in…
- UniProt
- O43353
- Protein
- Receptor-interacting serine/threonine-protein kinase 2
- EC
- 2.7.10.2, 2.7.11.1
- Experimental structures
- 56
- Predicted models
- 0
- Ligands
- 24
- Pockets
- 154 · 17 records with a druggable one
Structures
56 records of O43353 in the MolNFT archive: 56 experimental, 0 predicted.
| Entry | Title | Method | Chains | Ligands | Pockets |
|---|---|---|---|---|---|
| 2N7Z | Solution structure of RIP2 CARD | solution nmr | A | — | — |
| 2N7Z | Solution structure of RIP2 card | solution nmr | A | — | — |
| 2N83 | p75NTR DD:RIP2 CARD | solution nmr | B | — | — |
| 2N83 | P75NTR DD:RIP2 card | solution nmr | B | — | — |
| 4C8B | Structure of the kinase domain of human RIPK2 in complex with ponatinib | x-ray diffraction | A, B | — | — |
| 4C8B | Structure of the kinase domain of human RIPK2 in complex with ponatinib | x-ray diffraction | A, B | — | — |
| 5AR2 | RIP2 Kinase Catalytic Domain (1 - 310) | x-ray diffraction | A, B | — | — |
| 5AR2 | RIP2 kinase catalytic domain (1 - 310) | x-ray diffraction | A, B | — | — |
| 5AR3 | RIP2 Kinase Catalytic Domain (1 - 310) complex with AMP-PCP | x-ray diffraction | A, B | — | — |
| 5AR3 | RIP2 kinase catalytic domain (1 - 310) complex with AMP-pcp | x-ray diffraction | A, B | — | — |
| 5AR4 | RIP2 Kinase Catalytic Domain (1 - 310) complex with SB-203580 | x-ray diffraction | A, B | — | — |
| 5AR4 | RIP2 kinase catalytic domain (1 - 310) complex with sb-203580 | x-ray diffraction | A, B | — | — |
| 5AR5 | RIP2 Kinase Catalytic Domain (1 - 310) complex with Benzimidazole | x-ray diffraction | A, B | — | — |
| 5AR5 | RIP2 kinase catalytic domain (1 - 310) complex with benzimidazole | x-ray diffraction | A, B | — | — |
| 5AR7 | RIP2 Kinase Catalytic Domain (1 - 310) complex with Biaryl Urea | x-ray diffraction | A, B | — | — |
| 5AR7 | RIP2 kinase catalytic domain (1 - 310) complex with biaryl urea | x-ray diffraction | A, B | — | — |
| 5AR8 | RIP2 Kinase Catalytic Domain (1 - 310) complex with Biphenylsulfonamide | x-ray diffraction | A, B | XYW | 8 (best 0.81) |
| 5AR8 | RIP2 kinase catalytic domain (1 - 310) complex with biphenylsulfonamide | x-ray diffraction | A, B | — | — |
| 5J79 | The identification and pharmacological characterization of… | x-ray diffraction | A, B | 6GE, SO4 | 6 (best 0.83) |
| 5J79 | The identification and pharmacological characterization of 6-(tert… | x-ray diffraction | A, B | — | — |
| 5J7B | The identification and pharmacological characterization of… | x-ray diffraction | A, B | 6GD | 5 (best 0.82) |
| 5J7B | The identification and pharmacological characterization of 6-(tert… | x-ray diffraction | A, B | — | — |
| 5NG0 | Structure of RIP2K(L294F) with bound AMPPCP | x-ray diffraction | A, B | ACP, MG, CO | 5 (best 0.81) |
| 5NG0 | Structure of RIP2K(L294F) with bound amppcp | x-ray diffraction | A, B | ACP, MG, CO | — |
| 5NG2 | Structure of RIP2K(D146N) with bound Staurosporine | x-ray diffraction | A, B | STU, PO4 | 8 (best 0.79) |
| 5NG2 | Structure of RIP2K(D146N) with bound staurosporine | x-ray diffraction | A, B | STU, PO4 | — |
| 5NG3 | Structure of inactive kinase RIP2K(K47R) | x-ray diffraction | D, B, A, C | SO4 | 10 (best 0.79) |
| 5NG3 | Structure of inactive kinase RIP2K(K47R) | x-ray diffraction | D, B, A, C | SO4 | — |
| 5W5J | Identification of potent and selective RIPK2 inhibitors for the treatment of inflammatory diseases | x-ray diffraction | A, B | 9WS, SO4 | — |
| 5W5O | Identification of potent and selective RIPK2 inhibitors for the treatment of inflammatory diseases. | x-ray diffraction | A, B, C, D, E, F, G, H, I, J, K, L, M, N, O, P | 9XA | 20 (best 0.84) |
| 5W5O | Identification of potent and selective RIPK2 inhibitors for the treatment of inflammatory diseases. | x-ray diffraction | A, B, C, D, E, F, G, H, I, J, K, L, M, N, O, P | 9XA | — |
| 5YRN | Structure of RIP2 CARD domain | electron microscopy | A, B, C, D, E, F, G, H, I, J, K, L | — | 17 (best 0.79) |
| 5YRN | Structure of RIP2 card domain | electron microscopy | A, B, C, D, E, F, G, H, I, J, K, L | — | — |
| 6ES0 | Crystal structure of the kinase domain of human RIPK2 in complex with the activation loop targeting… | x-ray diffraction | A, B | BW8 | — |
| 6FU5 | Structure of the kinase domain of human RIPK2 in complex with the inhibitor CSLP18 | x-ray diffraction | A, B | E7N | — |
| 6GFJ | Structure of RIP2 CARD domain fused to crystallisable MBP tag | x-ray diffraction | A, B, C, D | GLC | 20 (best 0.75) |
| 6GFJ | Structure of RIP2 card domain fused to crystallisable mbp tag | x-ray diffraction | A, B, C, D | GLC | — |
| 6GGS | Structure of RIP2 CARD filament | electron microscopy | F, A, B, C, D, E, G, H, I, J | — | 7 (best 0.84) |
| 6GGS | Structure of RIP2 card filament | electron microscopy | F, A, B, C, D, E, G, H, I, J | — | — |
| 6HMX | RIP2 kinase catalytic domain complex with N(4,5DIMETHYL1HPYRAZOL3YL)… | x-ray diffraction | A, B | GEZ | — |
| 6RN8 | RIP2 kinase catalytic domain complex with 2(4[(1,3BENZOTHIAZOL5YL)… | x-ray diffraction | A, B | K9T, CA | — |
| 6RNA | RIP2 Kinase Catalytic Domain complex with 2({4[(1,3benzothiazol5yl)amino]6(2methylpropane2sulfonyl)q… | x-ray diffraction | A, B | KA2 | 6 (best 0.82) |
| 6RNA | RIP2 kinase catalytic domain complex with 2({4[(1,3BENZOTHIAZOL5YL)… | x-ray diffraction | A, B | KA2 | — |
| 6S1F | Structure of the kinase domain of human RIPK2 in complex with the inhibitor CSLP3 | x-ray diffraction | A, B, C, D | KRE | 17 (best 0.84) |
| 6S1F | Structure of the kinase domain of human RIPK2 in complex with the inhibitor CSLP3 | x-ray diffraction | A, B, C, D | KRE | — |
| 6SZE | RIP2 Kinase Catalytic Domain complex with 5-Amino-1-Phenylpyrazole-4-Carboxamide. | x-ray diffraction | A, B | M2B, CA | 7 (best 0.81) |
| 6SZE | RIP2 kinase catalytic domain complex with 5-amino-1-phenylpyrazole-4- carboxamide. | x-ray diffraction | A, B | M2B, CA | — |
| 6SZJ | RIP2 kinase catalytic domain complex with 5AMINO1TERTBUTYL3(3METHOXYPHENYL)1H PYRAZOLE4CARBOXAMIDE. | x-ray diffraction | A, B | M5W, CA | — |
| 6UL8 | RIP2 kinase catalytic domain complex with (5S,6S,8R)-2-(benzo[d]thiazol-5-yl)-6-hydroxy-4,5,6,7,8,9… | x-ray diffraction | A, B | Q9J, CA | 7 (best 0.81) |
| 6UL8 | RIP2 kinase catalytic domain complex with (5S,6S,8R)-2… | x-ray diffraction | A, B | Q9J, CA | — |
| 7OBS | Crystal structure of 14-3-3 sigma in complex with RIPK2 phosphopeptide | x-ray diffraction | B | — | 2 (best 0.51) |
| 7OBS | Crystal structure of 14-3-3 sigma in complex with RIPK2 phosphopeptide | x-ray diffraction | B | — | — |
| 7OBT | Crystal structure of 14-3-3 sigma in complex with RIPK2 phosphopeptide and stabilizer Fusicoccin-A | x-ray diffraction | B | FSC | 1 (best 0.59) |
| 7OBT | Crystal structure of 14-3-3 sigma in complex with RIPK2 phosphopeptide and stabilizer fusicoccin-a | x-ray diffraction | B | FSC | — |
| 8X2O | RIPK2 in complex with K252 | x-ray diffraction | A, B | 6IL | 8 (best 0.82) |
| O43353 | AlphaFold monomer V2.0 prediction for receptor-interacting SERINE/THREONINE-protein kinase 2… | — | — | — |
Ligands
- CA · Calcium ion · in 6 records
- SO4 · Sulfate ion · in 4 records
- 9XA · 4-{6-(tert-butylsulfonyl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]imidazo[1,2-a]pyridin-3-yl}-6-chloropyridin-2-amine · in 2 records
- ACP · Phosphomethylphosphonic acid adenylate ester · in 2 records
- CO · Cobalt (II) ion · in 2 records
- FSC · Fusicoccin · in 2 records
- GLC · alpha-D-glucopyranose · in 2 records
- KA2 · 2-[4-(1,3-benzothiazol-5-ylamino)-6-~{tert}-butylsulfonyl-quinazolin-7-yl]oxyethanol · in 2 records
- KRE · ~{N}-[3-[2-azanyl-5-(4-piperazin-1-ylphenyl)pyridin-3-yl]-5-methoxy-phenyl]methanesulfonamide · in 2 records
- M2B · 5-Amino-1-Phenylpyrazole-4-Carboxamide · in 2 records
- MG · Magnesium ion · in 2 records
- PO4 · Phosphate ion · in 2 records
- Q9J · (5S,6S,8R)-2-(1,3-benzothiazol-5-yl)-6-hydroxy-4,5,6,7, 8,9-hexahydro-5,8-methanopyrazolo[1,5-A][1, 3]diazocine-3-carboxamide · in 2 records
- STU · Staurosporine · in 2 records
- 6GD · 6-(tert-butylsulfonyl)-N-(5-fluoro-2H-indazol-3-yl)quinolin-4-amine · in 1 record
- 6GE · 4-methyl-3-{[6-(methylsulfonyl)quinolin-4-yl]amino}phenol · in 1 record
- 6IL · ~{N}-[(1~{R})-4-[4-[(6-fluoranyl-1,3-benzothiazol-5-yl)amino]thieno[2,3-d]pyrimidin-6-yl]cyclohex-3-en-1-yl]cyclopropanecarboxamide · in 1 record
- 9WS · N-(2-chlorophenyl)pyrazolo[1,5-a]pyridine-3-carboxamide · in 1 record
- BW8 · 2-[2-fluoranyl-4-[[2-fluoranyl-4-[2-(methylcarbamoyl) pyridin-4-yl]oxy-phenyl]carbamoylamino]phenyl]sulfanylethanoic acid · in 1 record
- E7N · ~{N}-[5-[2-azanyl-5-(4-piperazin-1-ylphenyl)pyridin-3-yl]-2-methoxy-phenyl]propane-1-sulfonamide · in 1 record
- GEZ · 6-~{tert}-butylsulfonyl-~{N}-(3,4-dimethyl-1~{H}-pyrazol-5-yl)-7-methoxy-quinolin-4-amine · in 1 record
- K9T · 2-[4-(1,3-benzothiazol-5-ylamino)-6-~{tert}-butylsulfonyl-quinazolin-7-yl]oxyethyl dihydrogen phosphate · in 1 record
- M5W · 5-amino-1-~{tert}-butyl-3-(3-methoxyphenyl)pyrazole-4-carboxamide · in 1 record
- XYW · 2,6-bis(fluoranyl)-N-[3-[5-[2-[(3-methylsulfonylphenyl)amino]pyrimidin-4-yl]-2-morpholin-4-yl-1,3-thiazol-4-yl]phenyl]benzenesulfonamide · in 1 record
Elsewhere
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.